Sio Gene Therapies

$2.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.04%) Today
$0.00 (0.00%) As of 9:37 PM UTC after-hours

Why Robinhood?

You can buy or sell SIOX and other stocks, options, and ETFs commission-free!

About SIOX

Sio Gene Therapies Inc. Common Stock, also called Sio Gene Therapies, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY. The listed name for SIOX is Sio Gene Therapies Inc. Common Stock.

CEO
Pavan Cheruvu
Employees
38
Headquarters
New York, New York
Founded
2014
Market Cap
138.62M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.17M
High Today
$3.06
Low Today
$2.81
Open Price
$2.92
Volume
1.41M
52 Week High
$4.15
52 Week Low
$1.90

Collections

SIOX Earnings

-$1.23
-$0.82
-$0.41
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Feb 10, Pre-Market

You May Also Like

IMTE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure